Journal
BLOOD
Volume 122, Issue 9, Pages 1599-1609Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-01-478156
Keywords
-
Categories
Funding
- University of Colorado Cancer Center Core Facilities [P30CA046934]
- American Academy of Pediatrics
- American Pediatric Society
- National Institute of Child Health and Human Development [K12-HD000850]
- American Cancer Society [RSG-08-291-01-LIB]
- National Institutes of Health [R01CA137078]
- Gabrielle's Angel Foundation for Cancer Research [030]
- Damon Runyon Cancer Research Foundation [CI-39-07]
- Brent Eley Foundation
- [CA98543]
- [CA114766]
Ask authors/readers for more resources
Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 85%. However, alterations to treatment strategies using available drugs are unlikely to provide significant improvement in survival or decrease therapy-associated toxicities. Here, we report ectopic expression of the Mer receptor tyrosine kinase in pre-B-cell ALL (B-ALL) cell lines and pediatric patient samples. Inhibition of Mer in B-ALL cell lines decreased activation of AKT and MAPKs and led to transcriptional changes, including decreased expression of antiapoptotic PRKCB gene and increase in proapoptotic BAX and BBC3 genes. Further, Mer inhibition promoted chemosensitization, decreased colony-forming potential in clonogenic assays, and delayed disease onset in a mouse xenograft model of leukemia. Our results identify Mer as a potential therapeutic target in B-ALL and suggest that inhibitors of Mer may potentiate lymphoblast killing when used in combination with chemotherapy. This strategy could reduce minimal residual disease and/or allow for chemotherapy dose reduction, thereby leading to improved event-free survival and reduced therapy-associated toxicity for patients with B-ALL. Additionally, Mer is aberrantly expressed in numerous other malignancies suggesting that this approach may have broad applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available